Allogene Therapeutics Inc (ALLO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Allogene Therapeutics Inc stock (ALLO) is currently trading at $2.21. Allogene Therapeutics Inc PS ratio (Price-to-Sales) is 7784.36. Analyst consensus price target for ALLO is $7.47. WallStSmart rates ALLO as Sell.
- ALLO PE ratio analysis and historical PE chart
- ALLO PS ratio (Price-to-Sales) history and trend
- ALLO intrinsic value — DCF, Graham Number, EPV models
- ALLO stock price prediction 2025 2026 2027 2028 2029 2030
- ALLO fair value vs current price
- ALLO insider transactions and insider buying
- Is ALLO undervalued or overvalued?
- Allogene Therapeutics Inc financial analysis — revenue, earnings, cash flow
- ALLO Piotroski F-Score and Altman Z-Score
- ALLO analyst price target and Smart Rating
Allogene Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Allogene Therapeutics Inc (ALLO) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around return on equity and price/sales. Significant fundamental concerns warrant caution or avoidance.
Allogene Therapeutics Inc (ALLO) Key Strengths (2)
Trading at 1.60x book value, attractively priced
61.10% held by institutions, strong professional interest
Supporting Valuation Data
Allogene Therapeutics Inc (ALLO) Areas to Watch (4)
Company is destroying shareholder value
Revenue declining -100.00%, a shrinking business
Very expensive at 7784.4x annual revenue
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Allogene Therapeutics Inc (ALLO) Detailed Analysis Report
Overall Assessment
This company scores 22/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 2 register as strengths (avg 8.0/10) while 4 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Institutional Own.. Valuation metrics including Price/Book (1.60) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Revenue Growth, Price/Sales. Some valuation metrics including Price/Sales (7784.36) suggest expensive pricing. Growth concerns include Revenue Growth at -100.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -53.40%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -53.40% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -100.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ALLO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ALLO's Price-to-Sales ratio of 7784.36x trades 130% above its historical average of 3378.36x (89th percentile), historically expensive. The current valuation is 33% below its historical high of 11631.14x set in Mar 2026, and 21093% above its historical low of 36.73x in Dec 2022. Over the past 12 months, the PS ratio has compressed from ~11631.1x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Allogene Therapeutics Inc (ALLO) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Allogene Therapeutics Inc operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue contracted 100% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -28M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Allogene Therapeutics Inc.
Bottom Line
Allogene Therapeutics Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Allogene Therapeutics Inc(ALLO)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Allogene Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and markets genetically engineered allogeneic T-cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California.